Despite the undeniable ability of viral vectors to deliver genetic payloads, and despite the incredible promise of this approach to treat a vast variety of diseases—including metabolic, cardiovascular ...

CDMOs are building cell and viral vector manufacturing facilities left and right, but Harvard says it just isn’t enough, at least to serve the Boston biotech hub. That is why a host of public and ...

Researchers at the National Institutes of Health (NIH) have developed a unique, improved viral vector to use in gene therapy for sickle cell disease. Using animal models, the new vector was shown to ...

Viral vector-based gene therapies hold immense promise for treating a multitude of diseases. However, their widespread adoption has been hindered by inefficient manufacturing methods and the absence ...

Bristol Myers Squibb’s cancer cell therapy Breyanzi. Johnson & Johnson and AstraZeneca’s recombinant COVID-19 vaccines. Novartis’ gene therapy Zolgensma. All of these, plus many others, are united by ...

Cell and gene therapies rely on engineered viruses to deliver them to their cellular destinations. While the progress of these types of medicines is evident in a growing number of FDA product ...

Researchers have developed a new and improved viral vector -- a virus-based vehicle that delivers therapeutic genes -- for use in gene therapy for sickle cell disease. In advanced lab tests using ...

With the introduction of curved smartphones, flexible electronic goods are gradually moving to the center stages of various markets. Flexible display technology is the culmination of the latest, ...